CMRX Stock Summary and Trading Ideas (Chimerix | NASDAQ:CMRX)

Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.

Chimerix trades on the NASDAQ stock market under the symbol CMRX.

As of April 24, 2024, CMRX stock price declined to $0.91 with 82,753 million shares trading.

CMRX has a beta of 0.95, meaning it tends to be less sensitive to market movements. CMRX has a correlation of 0.06 to the broad based SPY ETF.

CMRX has a market cap of $79.22 million. This is considered a Micro Cap stock.

Last quarter Chimerix reported $4,000 in Revenue and -$.20 earnings per share. This fell short of revenue expectation by $-56,000 and exceeded earnings estimates by $.04.

In the last 3 years, CMRX stock traded as high as $9.29 and as low as $.88.

The top ETF exchange traded funds that CMRX belongs to (by Net Assets): VTI, VXF, IWC, GERM.

CMRX has underperformed the market in the last year with a price return of -25.1% while the SPY ETF gained +24.2%. CMRX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -2.6% and -8.5%, respectively, while the SPY returned +4.6% and -2.7%, respectively.

CMRX support price is $.89 and resistance is $.96 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CMRX stock will trade within this expected range on the day.